Precision Pathways in MASLD — From Patient Selection to Outcome Assessment
Join us at the EASL Congress on May 29 from 16:30 to 17:30 for the GRIPonMASH session, and discover how precision approaches are shaping the future of MASLD care.
Register & Stay Updated
We invite you to register for the GRIPonMASH session at the EASL Congress 2026 in Barcelona. Please fill out the registration form below to secure your spot and stay updated with the latest information regarding the session.
Advancing Precision in MASLD Care
Join us at the EASL Congress 2026 for the GRIPonMASH session, Precision Pathways in MASLD — From Patient Selection to Outcome Assessment. This session will focus on one of the key challenges in clinical practice: identifying which patients are most likely to benefit from emerging therapies and how to effectively monitor disease progression and treatment response.
Through expert insights, we will explore strategies for patient stratification, treatment eligibility, and the assessment of fibrosis regression and clinical outcomes. Bringing together leading researchers and clinicians, this session offers a platform for discussion, knowledge exchange, and collaboration to advance precision approaches in MASLD care.
Session Highlights
- 16:30 – 16:40 Welcome & Status of the GRIPonMASH Project – Jo Massoels, Prof. Dr. Oscar H. Franco & Prof. Dr. Manuel Castro Cabezas
- 16:40 – 17:00 Identifying MASLD Patients Eligible for Emerging Therapies: Who Benefits Most from GLP-1 or Resmetirom? – Prof. Dr. Maja Thiele
- 17:00 – 17:20 Monitoring MASLD in Clinical Practice: Assessing Fibrosis Regression, Progression, and Prognostic Impact – Prof. Dr. Sven Franque
- 17:20 – 17:30 Closing Remarks & Future Perspectives – Jo Massoels, Prof. Dr. Oscar H. Franco & Prof. Dr. Manuel Castro Cabezas
Venue & Time Information
Date: May 29, 2026
Time: 16:30 to 17:30
Address: Fira Gran Via (North Access), C/Foc 37 – 08038 Barcelona, Spain
Location: Closed Industry Meeting Room, CC7.4/5
